USciences and TTC to Sponsor Pharmaceutical Leaders at a Key Conference in Philadelphia

TTC, llc and the University of the Sciences in Philadelphia (USciences) announce highly renowned leaders in the Pharmaceutical and CRO industries to speak at the "The 2nd Annual State of Clinical Development Cost" conference. This 2-day event will feature key speakers such as John Hubbard, Ph.D., F.C.P., Senior Vice President and Worldwide Head, Development Operations at Pfizer and Peter Aurup, MD., Vice President, Head Global Clinical Trial Operations at Merck. Dr. Hubbard will bring to light the current industry practices in the pharmaceutical industry while Dr. Aurup will be discussing the future challenges pharmaceutical companies will be facing.There will be five panels of highly renowned leaders that include industry leaders such as Peter Carberry, Sr. VP Global Development Operations at Astellas, Mitchell Katz, Ph.D., Executive Director, Medical Research Operations, at Purdue, Kate Tranotti, VP of Clinical Operations, ICON, and Alan Braverman, Vice President of North American Operations for PSI. All four panelists have been in the industry 25+ years and are experts in their fields.TTC "2nd Annual State of Clinical Development Cost" conference panels will address topics such as 'The Value of Cost Data to Upper Management', 'Working with Countries that are Difficult to Budget and Negotiate', 'Standard of Care Trends and Case Studies', 'Late Phase Study Planning and Budgeting', and a second day panel on 'CRO's'USciences has also announced that all proceeds from the conference will be devoted to pursue evidence based research issues that arise from those who attended the conference.Harold Glass, TTC Principal, and USciences Professor, summed up the upcoming conference as, "The "2nd Annual State of Clinical Development Cost" will focus on managing clinical development costs based on current industry trends, improving ROI, and increasing compliance. We are bringing together some of the best thinkers in the industry and academia for two days of notable keynote addresses, one-on-one talks, and panel discussions that covered the most up-to-date empirical research and experiences of leading edge companies."